Bhaskar Chaudhuri

Bhaskar joined Frazier Healthcare Partners in 2011 as Operating Partner. He brings significant operational experience in drug research, development, and commercialization in the United States, Europe, and emerging markets to the Life Science team. He also leads investments in later-stage companies as well as in international opportunities and is a co-founder of Arcutis (NASDAQ: ARQT), where he currently serves on the board. Bhaskar also serves on the board of Teligent (NASDAQ: TLGT) and is an advisor to the Johns Hopkins Berman Institute of Bioethics. He also served on the boards of directors of Silvergate Pharmaceuticals (acquired by CutisPharma), Corium International (acquired by Gurnet Point Capital), and Thesan Pharmaceuticals.

Prior to joining Frazier, Bhaskar was President of Valeant Pharmaceuticals, where he led Valeant’s international operations and business development activities. He joined Valeant through its acquisition of Dow Pharmaceutical Sciences, where he had been President and CEO. Before Dow, Bhaskar worked at Mylan Pharmaceuticals in several capacities including EVP of Scientific Affairs at Bertek Pharmaceuticals, a Mylan subsidiary, and as General Manager of the Dermatology Division. Earlier, he worked at Penederm, a skincare and drug-delivery company, as VP of R&D.

Bhaskar holds a Ph.D. in pharmaceutics, an M.S. in industrial pharmacy, and a B.S. in pharmacy.